Citi Pharma gets CCP approval to acquire Pakheim

Full buy of Pakheim under a May share deal; CCP cleared the merger on 9 October, with payment due by 31 December 2026 from operating cash.

The Competition Commission of Pakistan authorised Citi Pharma Limited to buy 100% of Pakheim International Pharma (Private) Limited.

The CCP order is dated 9 October 2026 (Case No. 1614/Merger-CCP/2026) under Section 31(1)(d)(i) of the Competition Act, 2010.

The deal follows a Share Purchase Agreement dated 6 May 2026 and still needs remaining legal and regulatory formalities.

Pakheim’s annual revenue is about Rs500 million; Citi Pharma aims to lift that to Rs5 billion in five years.

Payment is flexible until 31 December 2026 and is to be met from operational cash flows.

Read the full story